Home › Policy by country › Gender care in Sweden

Gender care in Sweden

Sweden was for a long time one of the most progressive countries in paediatric gender care and took the Dutch Protocol as a blueprint. Since 2019 the country has radically left that course. The Karolinska University Hospital stopped routinely prescribing puberty blockers to minors in 2021, and in 2022 Socialstyrelsen issued national guidelines that limit hormone treatment in minors almost entirely to research settings. Sweden has since been internationally regarded as the first country to openly distance itself from the gender-affirmative model.

The Karolinska decision (2021)

The Astrid Lindgren Children's Hospital, part of the Karolinska University Hospital in Stockholm, was for decades the leading centre for paediatric gender care in Sweden. In April 2021 the board published a striking guideline stating that puberty blockers and cross-sex hormones in minors are henceforth only to be prescribed within approved scientific research, with a few carefully weighed exceptions.

The direct cause was twofold: an internal audit evaluating the KEIRA study showed significant physical side effects in treated young people (including reduced bone density and growth inhibition), and the Karolinska ruled that the claim that puberty blockers are "fully reversible" was no longer tenable. The hospital explicitly referred to the Declaration of Helsinki on experimental medical research and concluded that prescribing these drugs to children outside a study setting was no longer ethically defensible.

The SBU report (2019, 2022)

The Statens beredning för medicinsk och social utvärdering (SBU), the Swedish institute for systematic evaluation of medical evidence, published a first report in 2019 on hormonal treatment of gender dysphoria in minors. The conclusion: the scientific basis is weak; most studies have methodological shortcomings and reliable long-term data is lacking. A follow-up evaluation in 2022 confirmed that the evidence base had not substantially improved since then. The SBU emphasised that hormonal interventions in minors must be considered experimental.

National guidelines Socialstyrelsen (2022)

On the basis of the Karolinska decision and the SBU reports, Socialstyrelsen (the Swedish national health authority) published new national guidelines in December 2022. The full English summary is available via Socialstyrelsen. SEGM has summarised the change of course as Sweden ends use of Dutch protocol.

The core message: in minors, the risks of hormonal treatment weigh more heavily than the possible benefits in virtually all cases. Psychotherapy and treatment of co-morbid problems (depression, autism, trauma) must come first. Hormonal interventions are only permitted in exceptional cases, after extensive multidisciplinary assessment, and preferably within clinical research.

Reasons for the change of course

Alongside the scientific evidence a number of concrete signals played a role. The Swedish documentary series "Trans-tåget" (The trans train, SVT 2019) showed how many adolescent girls with underlying psychological problems had been put on hormones after short pathways. Detransitioners such as Mikael Wallin testified about the lack of diagnostics and the difficulty of voicing doubts within the affirmative culture. At the same time the number of referrals rose explosively — with a shift from a few dozen to hundreds a year, especially adolescent girls — which raised questions about social contagion.

Current situation

For minors, medical gender care in Sweden is de facto limited to research protocols and very exceptional individual cases. Psychological care, family support and treatment of co-morbidity come first. For adults (18+) hormone therapy and surgery remain available through specialised clinics, but the diagnostic threshold has also been raised there.

International reach

The Swedish change of course was the first in a series of Northern European turns — followed by Finland, Norway, Denmark and the United Kingdom. The Cass Review cites the SBU evaluations explicitly as consistent with the findings of the University of York. Sweden is thereby one of the cornerstones of the international recalibration of paediatric gender care.